<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570022</url>
  </required_header>
  <id_info>
    <org_study_id>LB-TSA</org_study_id>
    <nct_id>NCT02570022</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine in Total Shoulder Arthroplasty</brief_title>
  <acronym>EXP-TSA</acronym>
  <official_title>Liposomal Bupivacaine Versus Interscalene Nerve Block for Pain Control After Shoulder Arthroplasty: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blinded, standard of care controlled clinical trial. All adult
      patients over eighteen desiring shoulder arthroplasty will be eligible. The study compares
      pain control and opioid consumption in patients undergoing shoulder arthroplasty between
      patients receiving liposomal bupivacaine and those who underwent a preoperative inter-scalene
      nerve block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: A randomized single blinded standard of care controlled clinical trial
      comparing pain management interventions. All patients over age eighteen and scheduled for
      primary shoulder arthroplasty (SA) a three fellowship trained surgeons will be eligible for
      inclusion. Patients will be excluded if their medical history presents known allergies or
      intolerance to dexamethasone, opioid or bupivacaine, substantial alcohol or drug abuse, and
      pregnancy.

      Liposomal Bupivacaine has a refrigerated shelf life of one month the investigational
      facility. Patients will be sequentially recruited into the randomization process. Liposomal
      Bupivacaine will be held by the Henry Ford hospital pharmacy up to one month prior to planned
      shoulder arthroplasty in anticipation of surgery on eligible patients. The sterile solutions
      will be delivered to and kept by the inpatient clinical pharmacy until the date of surgery
      and delivered to the operating room at the beginning of a surgical case. The current dose of
      Liposomal Bupivacaine has been chosen based on previously published data of local
      infiltrative analgesia with Liposomal Bupivacaine and one published study on Liposomal
      Bupivacaine efficacy.

      The week prior to surgery, patients will be randomized to receive Local infiltration
      anesthesia (LIA) with Liposomal Bupivacaine, or Inter-scalene nerve block (INB) using a
      computer generated sequence. The results of randomization will be securely delivered to the
      anesthesiologist and the surgeon the week prior. The anesthesiologist will view the assigned
      group to determine if a preoperative INB will be given. Depending on the randomization group
      either an Liposomal Bupivacaine solution will be delivered to the operating room for local
      infiltration or the anesthesiologist will perform a preoperative INB.

      Patients in the Liposomal Bupivacaine group will receive LIA with 10cc(133mg) of Liposomal
      Bupivacaine solution dissolved in 20cc of sterile saline before wound closure. The solution
      will be applied to the wound bed, muscles, and periosteum. The solution will be left
      unperturbed for five minutes. Thereafter the solution will be suctioned from the wound and
      the shoulder joint. Incisions will be closed in typical fashion and the wound dressed.The
      tourniquet will be deflated.

      Patients in the INB will receive postoperative ultrasound guided INB. Experienced
      anesthesiologists will apply all INBs in this study.

      Following the procedure pain will be accessed subjectively through visual analog scale and
      numeric rating scale pain scores, pain diaries given to the patient to record at home, pain
      summary scores at follow up visits and objectively through narcotic pain requirement. A blind
      observer will also access outcomes.

      Planned Data Analysis:

      Means and standard deviations, as well as medians and interquartile ranges will be computed
      for pain scores.These outcomes will be compared by Wilcoxon rank sum tests. The amount of
      pain medication and pain scores will be compared by Wilcoxon rank sum tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>four days postoperatively</time_frame>
    <description>Patients recorded pain levels every four hours using Visual analog scales for four days post operatively. Average daily pain was calculated for each patient. Range of the visual analog scale was 0-10, where 0 indicated a lower amount of pain and 10 indicated higher amount of pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine Equivalents</measure>
    <time_frame>four days postoperatively</time_frame>
    <description>Patients recorded opioid intake for four days postoperatively. Patients average daily morphine consumption was determined by averaging total patients daily morphine consumption by the number of patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inter-scalene nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Local infiltration of liposomal bupivacaine</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inter-scalene nerve block</intervention_name>
    <description>Pre-operative inter-scalene nerve block</description>
    <arm_group_label>Inter-scalene nerve block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivicaine was used for the inter-scalene nerve block.</description>
    <arm_group_label>Inter-scalene nerve block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18 scheduled for primary shoulder arthroplasty by three
             fellowship trained surgeons will be eligible for inclusion

        Exclusion Criteria:

          -  Patients will be excluded if their medical history presents known allergies or
             intolerance to dexamethasone, opioid or bupivacaine, substantial alcohol or drug
             abuse, and pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <results_first_submitted>June 8, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2016</results_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Kelechi Okoroha</investigator_full_name>
    <investigator_title>Sub-Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain control</keyword>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>exparel</keyword>
  <keyword>shoulder arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine</title>
          <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
Liposomal bupivacaine: Local infiltration of liposomal bupivacaine</description>
        </group>
        <group group_id="P2">
          <title>Inter-scalene Nerve Block</title>
          <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
Inter-scalene nerve block: Pre-operative inter-scalene nerve block
Ropivacaine: Ropivicaine was used for the inter-scalene nerve block.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Sixty patients were recruited for the study. Three patients declined to participate and were excluded before randomization. The remaining 57 patients were randomized with 31 patients in the INB group and 26 patients in the LB group. No patients were lost to follow-up. There were no statistical differences in any demographics between the 2 groups</population>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine</title>
          <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
Liposomal bupivacaine: Local infiltration of liposomal bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Inter-scalene Nerve Block</title>
          <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
Inter-scalene nerve block: Pre-operative inter-scalene nerve block
Ropivacaine: Ropivicaine was used for the inter-scalene nerve block.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" lower_limit="50" upper_limit="75"/>
                    <measurement group_id="B2" value="67.1" lower_limit="49" upper_limit="86"/>
                    <measurement group_id="B3" value="67.8" lower_limit="49" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Levels</title>
        <description>Patients recorded pain levels every four hours using Visual analog scales for four days post operatively. Average daily pain was calculated for each patient. Range of the visual analog scale was 0-10, where 0 indicated a lower amount of pain and 10 indicated higher amount of pain.</description>
        <time_frame>four days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
Liposomal bupivacaine: Local infiltration of liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Inter-scalene Nerve Block</title>
            <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
Inter-scalene nerve block: Pre-operative inter-scalene nerve block
Ropivacaine: Ropivicaine was used for the inter-scalene nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Levels</title>
          <description>Patients recorded pain levels every four hours using Visual analog scales for four days post operatively. Average daily pain was calculated for each patient. Range of the visual analog scale was 0-10, where 0 indicated a lower amount of pain and 10 indicated higher amount of pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Pain score Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.8"/>
                    <measurement group_id="O2" value="4.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Pain score Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.3"/>
                    <measurement group_id="O2" value="4.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Pain score Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.5"/>
                    <measurement group_id="O2" value="3.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Pain score Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.0"/>
                    <measurement group_id="O2" value="4.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Our hypothesis was that in patients undergoing shoulder arthroplasty, treatment with LB would lead to no significant differences in average daily pain scores. A power analysis was performed prior to the study to assess the primary hypothesis that a significant difference in average daily pain of 13mm on VAS will not be found between the INB and LB groups. With a power of 80% (beta level = 0.80, alpha level = 0.05), a sample size of 25 patients per group was obtained</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>This analysis corresponds to the visual analog scale and morphine equivalent data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morphine Equivalents</title>
        <description>Patients recorded opioid intake for four days postoperatively. Patients average daily morphine consumption was determined by averaging total patients daily morphine consumption by the number of patients.</description>
        <time_frame>four days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
Liposomal bupivacaine: Local infiltration of liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Inter-scalene Nerve Block</title>
            <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
Inter-scalene nerve block: Pre-operative inter-scalene nerve block
Ropivacaine: Ropivicaine was used for the inter-scalene nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Morphine Equivalents</title>
          <description>Patients recorded opioid intake for four days postoperatively. Patients average daily morphine consumption was determined by averaging total patients daily morphine consumption by the number of patients.</description>
          <units>mg of morphine equivalent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Morphine equivalents used Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="9.2"/>
                    <measurement group_id="O2" value="21.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Morphine equivalents used Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="9.7"/>
                    <measurement group_id="O2" value="9.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Morphine equivalents used Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="16.9"/>
                    <measurement group_id="O2" value="5.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Morphine equivalents used Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="4.1"/>
                    <measurement group_id="O2" value="2.2" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine</title>
          <description>Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
Liposomal bupivacaine: Local infiltration of liposomal bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Inter-scalene Nerve Block</title>
          <description>Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
Inter-scalene nerve block: Pre-operative inter-scalene nerve block
Ropivacaine: Ropivicaine was used for the inter-scalene nerve block.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Phrenic nerve palsy</sub_title>
                <description>One patient in the INB group suffered a prolonged phrenic nerve palsy requiring readmission for elevation of the right hemi-diaphragm with respiratory compromise.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Use of the VAS, which is a simple one-dimensional analog rating scale, to assess the patients subjective pain level. Patient compliance is a limitation, with maintenance of pain dairies decreasing as time from surgery progressed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kelechi Okoroha</name_or_title>
      <organization>Henry Ford Hospital</organization>
      <phone>8324239895</phone>
      <email>krokoroha@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

